Alexandros Makriyannis

List of Publications by Year
in descending order

477	25,127	7672	13274
papers	citations	79 h-index	135 g-index

485	485	485	16284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. Brain Research, 2022, 1774, 147721.	1.1	5
2	Nâ€Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. British Journal of Pharmacology, 2022, 179, 1679-1694.	2.7	6
3	1-, 2- and 3-AG as substrates of the endocannabinoid enzymes and endogenous ligands of the cannabinoid receptor 1. Biochemical and Biophysical Research Communications, 2022, 591, 31-36.	1.0	6
4	Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. Nature, 2022, 601, 452-459.	13.7	153
5	Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists. European Journal of Medicinal Chemistry, 2022, 230, 114027.	2.6	1
6	PKC is an indispensable factor in promoting environmental toxin chromium-mediated transformation and drug resistance. Aging, 2022, 14, 1678-1690.	1.4	0
7	Inhibition of triple negative breast cancer-associated inflammation, tumor growth and brain colonization by targeting monoacylglycerol lipase. Scientific Reports, 2022, 12, 5328.	1.6	6
8	Role of CB₁ receptors in the acute regulation of small intestinal permeability: effects of high-fat diet. American Journal of Physiology - Renal Physiology, 2022, 323, G219-G238.	1.6	6
9	Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression. Cannabis and Cannabinoid Research, 2021, 6, 401-412.	1.5	8
10	Cannabis sativa: an overview. , 2021, , 603-624.		12
11	Interference with TGFÎ²1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. Molecules, 2021, 26, 866.	1.7	10
12	The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology, 2021, 185, 108450.	2.0	13
13	Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. Journal of Medicinal Chemistry, 2021, 64, 3870-3884.	2.9	8
14	Maternal Dietary Fatty Acids and Their Relationship to Derived Endocannabinoids in Human Milk. Journal of Human Lactation, 2021, 37, 813-820.	0.8	6
15	Nâ€acylethanolamineâ€hydrolysing acid amidase: A new potential target to treat paclitaxelâ€induced neuropathy. European Journal of Pain, 2021, 25, 1367-1380.	1.4	5
16	Oxa-adamantyl cannabinoids. Bioorganic and Medicinal Chemistry Letters, 2021, 38, 127882.	1.0	3
17	Design and Structureâ€“Activity Relationships of Isothiocyanates as Potent and Selective N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 5956-5972.	2.9	4
18	Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior, 2021, 206, 173192.	1.3	9

#	Article	IF	Citations
19	N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice. Neurotherapeutics, 2021, 18, 1815-1833.	2.1	6
20	Rational Remodeling of Atypical Scaffolds for the Design of Photoswitchable Cannabinoid Receptor Tools. Journal of Medicinal Chemistry, 2021, 64, 13752-13765.	2.9	9
21	N-Acylethanolamine Acid Amidase Inhibition Potentiates Morphine Analgesia and Delays the Development of Tolerance. Neurotherapeutics, 2021, 18, 2722-2736.	2.1	7
22	Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors. ChemMedChem, 2021, , .	1.6	3
23	A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoid Receptor 1. Journal of the American Chemical Society, 2021, 143, 16320-16325.	6.6	44
24	Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression. Cannabis and Cannabinoid Research, 2021, , .	1.5	5
25	Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115195.	1.4	17
26	Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARÎ± dependent. Molecular Metabolism, 2020, 42, 101087.	3.0	23
27	Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite. Frontiers in Pharmacology, 2020, 11, 575691.	1.6	2
28	Conformational gating, dynamics and allostery in human monoacylglycerol lipase. Scientific Reports, 2020, 10, 18531.	1.6	8
29	Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. Brain and Behavior, 2020, 10, e01850.	1.0	10
30	Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome. Medicina (Lithuania), 2020, 56, 573.	0.8	9
31	Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 462-468.	1.3	4
32	Synthesis of Functionalized Cannabilactones. Molecules, 2020, 25, 684.	1.7	5
33	Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures. Cell, 2020, 180, 655-665.e18.	13.5	212
34	Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 119-127.	1.3	7
35	Endocannabinoid regulation of homeostatic feeding and stressâ€induced alterations in food intake in male rats. British Journal of Pharmacology, 2019, 176, 1524-1540.	2.7	20
36	Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. Acta Pharmacologica Sinica, 2019, 40, 365-373.	2.8	37

#	Article	IF	Citations
37	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB₁ receptors. British Journal of Pharmacology, 2019, 176, 4653-4665.	2.7	46
38	The novel cannabinoid CB 1 receptor agonist AM11101 increases food intake in female rats. British Journal of Pharmacology, 2019, 176, 3972-3982.	2.7	4
39	Probing the CB₁ Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist. Molecular Pharmacology, 2019, 96, 619-628.	1.0	4
40	Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor. Molecules, 2019, 24, 3559.	1.7	5
41	Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. Bioorganic and Medicinal Chemistry, 2019, 27, 115096.	1.4	9
42	Biochemical and Proteomic Characterization of Recombinant Human Î±/Î² Hydrolase Domain 6. Scientific Reports, 2019, 9, 890.	1.6	10
43	Cannabis in Veterinary Medicine: Cannabinoid Therapies for Animals. , 2019, , 121-155.		20
44	Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity. Frontiers in Physiology, 2019, 10, 704.	1.3	37
45	The sesquiterpene beta-caryophyllene oxide attenuates ethanol drinking and place conditioning in mice. Heliyon, 2019, 5, e01915.	1.4	13
46	Endocannabinoid Metabolome Characterization of Milk from Guatemalan Women Living in the Western Highlands. Current Developments in Nutrition, 2019, 3, nzz018.	0.1	9
47	A new antibiotic selectively kills Gram-negative pathogens. Nature, 2019, 576, 459-464.	13.7	456
48	The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders. , 2019, , 43-54.		0
49	Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. Neuropharmacology, 2019, 144, 327-336.	2.0	24
50	Cannabinoid-induced lower lip retraction in rats. Psychopharmacology, 2019, 236, 1199-1206.	1.5	3
51	Crystal Structure of the Human Cannabinoid Receptor CB2. Cell, 2019, 176, 459-467.e13.	13.5	268
52	Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment. Bioorganic and Medicinal Chemistry, 2019, 27, 55-64.	1.4	10
53	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry,the, 2019, 6, 35-45.	3.7	125
54	Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Molecular Pharmacology, 2019, 95, 155-168.	1.0	42

#	Article	IF	Citations
55	Antidotes for Acute Cannabinoid Intoxication. FASEB Journal, 2019, 33, 804.2.	0.2	0
56	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. FASEB Journal, 2019, 33, lb384.	0.2	0
57	Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase. Scientific Reports, 2018, 8, 1719.	1.6	28
58	Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Scientific Reports, 2018, 8, 2935.	1.6	9
59	Secretion, isotopic labeling and deglycosylation of N-acylethanolamine acid amidase for biophysical studies. Protein Expression and Purification, 2018, 145, 108-117.	0.6	2
60	Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 485-493.	1.3	4
61	Hydrogen-Deuterium Exchange Mass Spectrometry to Study Protein Complexes. Methods in Molecular Biology, 2018, 1764, 153-171.	0.4	33
62	Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology, 2018, 131, 200-208.	2.0	37
63	Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle. Genes and Cancer, 2018, 10, 39-51.	0.6	12
64	Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins. Journal of Medicinal Chemistry, 2018, 61, 11199-11208.	2.9	7
65	Fluorescent probes for G-protein-coupled receptor drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 933-947.	2.5	37
66	Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 551-563.	1.3	32
67	Endocannabinoid Metabolome Characterization of Transitional and Mature Human Milk. Nutrients, 2018, 10, 1294.	1.7	26
68	Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. British Journal of Pharmacology, 2018, 175, 4371-4385.	2.7	22
69	(R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry, 2018, 61, 8639-8657.	2.9	12
70	Oximes short-acting CB1 receptor agonists. Bioorganic and Medicinal Chemistry, 2018, 26, 4963-4970.	1.4	9
71	Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure. Pharmaceuticals, 2018, 11, 50.	1.7	6
72	The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology, 2018, 836, 34-43.	1.7	9

#	Article	IF	Citations
73	A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells. Oncotarget, 2018, 9, 6308-6319.	0.8	8
74	N -acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N -acylethanolamine levels and macrophage activation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 474-484.	1.2	37
75	Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor. Psychopharmacology, 2017, 234, 1029-1043.	1.5	11
76	Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. ACS Chemical Neuroscience, 2017, 8, 1338-1347.	1.7	6
77	Gî±_s signalling of the CB₁ receptor and the influence of receptor number. British Journal of Pharmacology, 2017, 174, 2545-2562.	2.7	75
78	Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis. Journal of Proteome Research, 2017, 16, 2419-2428.	1.8	12
79	Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrology Dialysis Transplantation, 2017, 32, 1655-1665.	0.4	42
80	Cannabinoid CB₁ Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 314-323.	1.3	8
81	The role of human monoacylglycerol lipase (hMAGL) binding pocket in breakup of unsaturated phospholipid membranes. Analytical Biochemistry, 2017, 536, 90-95.	1.1	2
82	Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon. Journal of Molecular Neuroscience, 2017, 63, 115-122.	1.1	9
83	Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature, 2017, 547, 468-471.	13.7	379
84	C1â€²-Azacycloalkyl Hexahydrocannabinols. Journal of Organic Chemistry, 2017, 82, 7839-7849.	1.7	7
85	Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets. Biochemical Pharmacology, 2017, 128, 1-11.	2.0	63
86	Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains. Methods in Enzymology, 2017, 593, 217-235.	0.4	6
87	Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. Journal of Clinical Investigation, 2017, 127, 4148-4162.	3.9	128
88	CBâ‚•receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.. Behavioral Neuroscience, 2017, 131, 304-311.	0.6	10
89	Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells. Oncotarget, 2017, 8, 30992-31002.	0.8	7
90	Endocannabinoid Signaling Regulates Sleep Stability. PLoS ONE, 2016, 11, e0152473.	1.1	65

#	Article	IF	Citations
91	[INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats. Behavioural Pharmacology, 2016, 27, 211-214.	0.8	8
92	Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. Journal of Medicinal Chemistry, 2016, 59, 6903-6919.	2.9	20
93	CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats. Journal of Psychopharmacology, 2016, 30, 482-491.	2.0	8
94	Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a Â-Opioid Agonist in THC-Treated Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 334-341.	1.3	7
95	Acute and chronic effects of cannabidiol on Î”â¹-tetrahydrocannabinol (Î”â¹-THC)-induced disruption in stop signal task performance.. Experimental and Clinical Psychopharmacology, 2016, 24, 320-330.	1.3	22
96	Biocatalyzed Regioselective Synthesis in Undergraduate Organic Laboratories: Multistep Synthesis of 2-Arachidonoylglycerol. Journal of Chemical Education, 2016, 93, 2080-2083.	1.1	7
97	Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. Pharmacological Research, 2016, 114, 75-89.	3.1	16
98	Crystal Structure of the Human Cannabinoid Receptor CB1. Cell, 2016, 167, 750-762.e14.	13.5	468
99	A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Î” 9 -THC in rats. Pharmacology Biochemistry and Behavior, 2016, 148, 46-52.	1.3	3
100	Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Psychopharmacology, 2016, 233, 1867-1877.	1.5	19
101	A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models. Psychopharmacology, 2016, 233, 2265-2275.	1.5	17
102	Cannabis sativa and Hemp. , 2016, , 735-754.		92
103	Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Psychopharmacology, 2016, 233, 1879-1888.	1.5	29
104	Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling. Behavioural Pharmacology, 2016, 27, 258-269.	0.8	12
105	17Î²-estradiol (E2) in membranes: Orientation and dynamic properties. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 344-353.	1.4	8
106	Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology, 2016, 41, 2283-2293.	2.8	54
107	Comparisons of Â9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 125-133.	1.3	33
108	Specific Inter-residue Interactions as Determinants of Human Monoacylglycerol Lipase Catalytic Competency. Journal of Biological Chemistry, 2016, 291, 2556-2565.	1.6	10

#	Article	IF	Citations
109	Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). Journal of Medicinal Chemistry, 2016, 59, 44-60.	2.9	49
110	Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functionalNf1to apoptosis in the absence of protein kinase C. Oncotarget, 2016, 7, 84326-84337.	0.8	5
111	Medicinal chemistry of cannabinoids. Clinical Pharmacology and Therapeutics, 2015, 97, 553-558.	2.3	112
112	Impaired neurogenesis by <scp>HIV</scp>â€1â€<scp>G</scp>p120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme. British Journal of Pharmacology, 2015, 172, 4603-4614.	2.7	21
113	In vitro and nonâ€invasive inÂvivo effects of the cannabinoidâ€1 receptor agonist <scp>AM</scp>841 on gastrointestinal motor function in the rat. Neurogastroenterology and Motility, 2015, 27, 1721-1735.	1.6	24
114	Diet-Induced Changes in n-3- and n-6-Derived Endocannabinoids and Reductions in Headache Pain and Psychological Distress. Journal of Pain, 2015, 16, 707-716.	0.7	58
115	Novel tail and head group prostamide probes. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1228-1231.	1.0	3
116	Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Letters, 2015, 56, 1411-1415.	0.7	10
117	<scp>AM</scp>841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. British Journal of Pharmacology, 2015, 172, 2406-2418.	2.7	28
118	13-Methylarachidonic Acid Is a Positive Allosteric Modulator of Endocannabinoid Oxygenation by Cyclooxygenase. Journal of Biological Chemistry, 2015, 290, 7897-7909.	1.6	25
119	Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Frontiers in Psychiatry, 2015, 6, 41.	1.3	48
120	Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Psychopharmacology, 2015, 232, 2751-2761.	1.5	19
121	Molecular-Interaction and Signaling Profiles of AM3677, a Novel Covalent Agonist Selective for the Cannabinoid 1 Receptor. ACS Chemical Neuroscience, 2015, 6, 1400-1410.	1.7	22
122	3â€²-Functionalized Adamantyl Cannabinoid Receptor Probes. Journal of Medicinal Chemistry, 2015, 58, 3104-3116.	2.9	23
123	Hydrogenâ€Bonded His93 As a Sensitive Probe for Identifying Inhibitors of the Endocannabinoid Transport Protein <scp>FABP</scp>7. Chemical Biology and Drug Design, 2015, 85, 534-540.	1.5	1
124	Probing the Carboxyester Side Chain in Controlled Deactivation (â^')-Î”⁸-Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2015, 58, 665-681.	2.9	26
125	Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1â€“Dependent Withdrawal. Biological Psychiatry, 2015, 77, 475-487.	0.7	179
126	N â€Acylethanolamineâ€hydrolyzing acid amidase inhibition increases colon N â€palmitoylethanolamine levels and counteracts murine colitis. FASEB Journal, 2015, 29, 650-661.	0.2	93

#	Article	IF	Citations
127	Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. Neuropharmacology, 2014, 87, 214-221.	2.0	24
128	Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats. Psychopharmacology, 2014, 231, 489-500.	1.5	18
129	C-Ring Cannabinoid Lactones: A Novel Cannabinergic Chemotype. ACS Medicinal Chemistry Letters, 2014, 5, 400-404.	1.3	11
130	The cannabinoid <scp>CB</scp>₂ receptor agonist <scp>AM</scp>1241 enhances neurogenesis in <scp>GFAP</scp>/<scp>G</scp>p120 transgenic mice displaying deficits in neurogenesis. British Journal of Pharmacology, 2014, 171, 468-479.	2.7	72
131	2012 Division of Medicinal Chemistry Award Address. Trekking the Cannabinoid Road: A Personal Perspective. Journal of Medicinal Chemistry, 2014, 57, 3891-3911.	2.9	47
132	Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 86-93.	2.5	18
133	CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. Psychopharmacology, 2014, 231, 4291-4300.	1.5	21
134	Terpenes and Lipids of the Endocannabinoid and Transient-Receptor-Potential-Channel Biosignaling Systems. ACS Chemical Neuroscience, 2014, 5, 1097-1106.	1.7	17
135	Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors. PLoS ONE, 2014, 9, e109115.	1.1	59
136	Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Molecular Psychiatry, 2013, 18, 813-823.	4.1	267
137	The Interaction of Fatty Acid Amide Hydrolase (FAAH) Inhibitors with an Anandamide Carrier Protein Using 19 F-NMR. AAPS Journal, 2013, 15, 477-482.	2.2	7
138	Diuretic effects of cannabinoid agonists in mice. European Journal of Pharmacology, 2013, 721, 64-69.	1.7	22
139	Controlled-Deactivation Cannabinergic Ligands. Journal of Medicinal Chemistry, 2013, 56, 10142-10157.	2.9	26
140	Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. Pharmacology Biochemistry and Behavior, 2013, 109, 16-22.	1.3	15
141	Therapeutic modulation of cannabinoid lipid signaling: Metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sciences, 2013, 92, 482-491.	2.0	9
142	Inhibition of fatty acid amide hydrolase activates <scp>Nrf2</scp> signalling and induces heme oxygenase 1 transcription in breast cancer cells. British Journal of Pharmacology, 2013, 170, 489-505.	2.7	35
143	Novel Adamantyl Cannabinoids as CB1 Receptor Probes. Journal of Medicinal Chemistry, 2013, 56, 3904-3921.	2.9	30
144	Active-Site Inhibitors Modulate the Dynamic Properties of Human Monoacylglycerol Lipase: A Hydrogen Exchange Mass Spectrometry Study. Biochemistry, 2013, 52, 5016-5026.	1.2	17

#	Article	IF	Citations
145	Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Science, 2013, 22, 774-787.	3.1	37
146	Diuretic Effects of Cannabinoids. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 8-14.	1.3	24
147	Analysis of Tolerance and Behavioral/Physical Dependence during Chronic CB₁Agonist Treatment: Effects of CB₁Agonists, Antagonists, and Noncannabinoid Drugs. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 319-328.	1.3	38
148	Highly Predictive Ligandâ€based Pharmacophore and Homology Models of ABHD6. Chemical Biology and Drug Design, 2013, 81, 382-388.	1.5	11
149	Cannabinoid Discrimination and Antagonism by CB₁Neutral and Inverse Agonist Antagonists. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 561-567.	1.3	42
150	Novel Insights into CB₁ Cannabinoid Receptor Signaling: A Key Interaction Identified between the Extracellular-3 Loop and Transmembrane Helix 2. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 189-197.	1.3	18
151	AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. Journal of Psychopharmacology, 2013, 27, 564-571.	2.0	31
152	Effects of a novel CB1 agonist on visual attention in male rats: Role of strategy and expectancy in task accuracy.. Experimental and Clinical Psychopharmacology, 2013, 21, 416-425.	1.3	11
153	Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. PLoS ONE, 2013, 8, e85073.	1.1	45
154	CB1â€Like Behavioral Effects of the Novel FAAH inhibitor AM3506. FASEB Journal, 2013, 27, lb532.	0.2	0
155	Targeting the Endocannabinoid System for Neuroprotection: A F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA. Journal of Pharmaceutics & Pharmacology, 2013, 1, .	0.5	2
156	Integrated Ligand Based Pharmacophore Model Derived from Diverse FAAH Covalent Ligand Classes. Current Computer-Aided Drug Design, 2012, 8, 330-334.	0.8	0
157	Prevention of Fibrosis Progression in CCl₄-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 629-637.	1.3	56
158	Î”9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behavioural Pharmacology, 2012, 23, 802-805.	0.8	75
159	Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase â€“ Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology. Neurotherapeutics, 2012, 9, 801-813.	2.1	49
160	Enzymatic synthesis of N-acylethanolamines: direct method for the aminolysis of esters. Tetrahedron Letters, 2012, 53, 5753-5755.	0.7	29
161	Sulfonyl Fluoride Inhibitors of Fatty Acid Amide Hydrolase. Journal of Medicinal Chemistry, 2012, 55, 10074-10089.	2.9	43
162	Mass Spectrometric Characterization of Human N-Acylethanolamine-hydrolyzing Acid Amidase. Journal of Proteome Research, 2012, 11, 972-981.	1.8	30

#	Article	IF	Citations
163	Endocannabinoid Enzyme Engineering: Soluble Human Thio-Monoacylglycerol Lipase (sol-S-hMGL). ACS Chemical Neuroscience, 2012, 3, 393-399.	1.7	9
164	Application of chemoenzymatic hydrolysis in the synthesis of 2-monoacylglycerols. Tetrahedron, 2012, 68, 5422-5428.	1.0	8
165	Enantioselective synthesis of (10S)- and (10R)-methyl-anandamides. Tetrahedron, 2012, 68, 6329-6337.	1.0	6
166	Synthesis and characterization of a compact tricyclic resorcinol from (+)- and (â^')-3-pinanol. Tetrahedron Letters, 2012, 53, 4636-4638.	0.7	5
167	The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotineâ€induced dopamine elevations in the nucleus accumbens shell in rats. British Journal of Pharmacology, 2012, 165, 2539-2548.	2.7	56
168	Assay and inhibition of diacylglycerol lipase activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4585-4592.	1.0	16
169	C3-Heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5322-5325.	1.0	27
170	Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking. PLoS ONE, 2012, 7, e29900.	1.1	61
171	Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal antiâ€inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain and Behavior, 2012, 2, 155-177.	1.0	47
172	Inhibiting fatty acid amide hydrolase normalizes endotoxinâ€induced enhanced gastrointestinal motility in mice. British Journal of Pharmacology, 2012, 165, 1556-1571.	2.7	51
173	AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology, 2012, 220, 417-426.	1.5	23
174	Biochemical and Mass Spectrometric Characterization of Human N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition. PLoS ONE, 2012, 7, e43877.	1.1	33
175	Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opinion on Drug Discovery, 2011, 6, 995-1025.	2.5	20
176	Binding between a Distal C-Terminus Fragment of Cannabinoid Receptor 1 and Arrestin-2. Biochemistry, 2011, 50, 2223-2234.	1.2	19
177	A Methodology for Radiolabeling of the Endocannabinoid 2-Arachidonoylglycerol (2-AG). Journal of Organic Chemistry, 2011, 76, 2049-2055.	1.7	14
178	Approximating Protein Flexibility through Dynamic Pharmacophore Models: Application to Fatty Acid Amide Hydrolase (FAAH). Journal of Chemical Information and Modeling, 2011, 51, 3247-3253.	2.5	20
179	The interaction of cannabinoid receptor agonists, CP55940 and WIN55212-2 with membranes using solid state 2H NMR. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2095-2101.	1.4	10
180	Mass Spectrometry-based Proteomics of Human Cannabinoid Receptor 2: Covalent Cysteine 6.47(257)-Ligand Interaction Affording Megagonist Receptor Activation. Journal of Proteome Research, 2011, 10, 4789-4798.	1.8	35

#	Article	IF	Citations
181	The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience, 2011, 193, 21-33.	1.1	28
182	Cannabinergic aminoalkylindoles, including AM678=JWH018 found in â€˜Spiceâ€™, examined using drug (Î”9-tetrahydrocannabinol) discrimination for rats. Behavioural Pharmacology, 2011, 22, 498-507.	0.8	46
183	Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood, 2011, 117, 827-838.	0.6	29
184	Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain, 2011, 152, 1976-1987.	2.0	55
185	The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacology Biochemistry and Behavior, 2011, 97, 537-543.	1.3	46
186	Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects. Pharmacology Biochemistry and Behavior, 2011, 98, 493-502.	1.3	55
187	Conformationally constrained analogs of BAY 59â€“3074 as novel cannabinoid receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5999-6002.	1.0	12
188	Aspirin-Triggered Metabolites of EFAs. Chemistry and Biology, 2011, 18, 1208-1209.	6.2	5
189	Human Cannabinoid 1 GPCR C-Terminal Domain Interacts with Bilayer Phospholipids to Modulate the Structure of its Membrane Environment. AAPS Journal, 2011, 13, 92-98.	2.2	18
190	Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology, 2011, 216, 355-365.	1.5	13
191	A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-Induced Excitotoxicity. Journal of Molecular Neuroscience, 2011, 43, 493-502.	1.1	45
192	Chemoenzymatic synthesis of 2-arachidonoylglycerol, an endogenous ligand for cannabinoid receptors. Tetrahedron Letters, 2011, 52, 1149-1150.	0.7	11
193	Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.. Journal of Biological Chemistry, 2011, 286, 24534.	1.6	0
194	Selective modulation of the endocannabinoid system for targeted protection in kainic acid models of excitotoxicity. FASEB Journal, 2011, 25, lb420.	0.2	0
195	Antinociceptive Effects of Racemic AM1241 and Its Chirally Synthesized Enantiomers: Lack of Dependence upon Opioid Receptor Activation. AAPS Journal, 2010, 12, 147-157.	2.2	18
196	Discriminative stimulus functions of methanandamide and â^†9-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology, 2010, 208, 87-98.	1.5	30
197	The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacology Biochemistry and Behavior, 2010, 95, 479-484.	1.3	45
198	Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists. Pharmacology Biochemistry and Behavior, 2010, 96, 75-81.	1.3	7

#	Article	IF	Citations
199	The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacology Biochemistry and Behavior, 2010, 97, 179-184.	1.3	68
200	Identification of Endocannabinoids and Related N-Acylethanolamines in Tetrahymena. A New Class of Compounds for Tetrahymena. Protist, 2010, 161, 452-465.	0.6	14
201	Antagonism of â^†9-THC induced behavioral effects by rimonabant: Time course studies in rats. European Journal of Pharmacology, 2010, 648, 133-138.	1.7	19
202	Design and Synthesis of (13S)â€Methylâ€Substituted Arachidonic Acid Analogues: Templates for Novel Endocannabinoids. Chemistry - A European Journal, 2010, 16, 4091-4099.	1.7	11
203	Intramolecular Heck reactions of aryl chlorides with alkynes. Tetrahedron Letters, 2010, 51, 1517-1522.	0.7	23
204	The conformations of 17Î²-estradiol (E2) and 17Î±-estradiol as determined by solution NMR. Tetrahedron Letters, 2010, 51, 3465-3469.	0.7	21
205	hCB2 Ligand-Interaction Landscape: CysteineÂResidues Critical to Biarylpyrazole AntagonistÂBinding Motif and Receptor Modulation. Chemistry and Biology, 2010, 17, 1132-1142.	6.2	27
206	Inhibitor of Fatty Acid Amide Hydrolase Normalizes Cardiovascular Function in Hypertension without Adverse Metabolic Effects. Chemistry and Biology, 2010, 17, 1256-1266.	6.2	85
207	Inverse agonism of cannabinoid CB₁ receptors potentiates LiClâ€induced nausea in the conditioned gaping model in rats. British Journal of Pharmacology, 2010, 161, 336-349.	2.7	56
208	A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. British Journal of Pharmacology, 2010, 161, 629-642.	2.7	154
209	Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterology and Motility, 2010, 22, 787-e223.	1.6	45
210	Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. Journal of Lipid Research, 2010, 51, 1416-1423.	2.0	118
211	Endocannabinoids Are Expressed in Bone Marrow Stromal Niches and Play a Role in Interactions of Hematopoietic Stem and Progenitor Cells with the Bone Marrow Microenvironment. Journal of Biological Chemistry, 2010, 285, 35471-35478.	1.6	14
212	Mass Spectrometry-Based GPCR Proteomics: Comprehensive Characterization of the Human Cannabinoid 1 Receptor. Journal of Proteome Research, 2010, 9, 1746-1753.	1.8	21
213	Heteroadamantyl Cannabinoids. Journal of Medicinal Chemistry, 2010, 53, 5656-5666.	2.9	36
214	Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sciences, 2010, 86, 615-623.	2.0	80
215	Novel 1â€²,1â€²-Chain Substituted Hexahydrocannabinols: 9Î²-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist. Journal of Medicinal Chemistry, 2010, 53, 6996-7010.	2.9	48
216	Novel and Efficient One-Step Parallel Synthesis of Dibenzopyranones via Suzukiâ^'Miyaura Cross Coupling. ACS Combinatorial Science, 2010, 12, 664-669.	3.3	49

#	Article	IF	Citations
217	Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. European Neuropsychopharmacology, 2010, 20, 112-122.	0.3	69
218	Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism. Molecular BioSystems, 2010, 6, 1381.	2.9	12
219	Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. Journal of Clinical Investigation, 2010, 120, 2953-2966.	3.9	393
220	Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113. Pharmacology Biochemistry and Behavior, 2009, 91, 303-306.	1.3	37
221	Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Diseases, 2009, 15, 1678-1685.	0.9	156
222	Refined homology model of monoacylglycerol lipase: toward a selective inhibitor. Journal of Computer-Aided Molecular Design, 2009, 23, 799-806.	1.3	11
223	Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacology, 2009, 203, 229-239.	1.5	14
224	Cognitive effects of psychotomimetic drugs in rats discriminating number cues. Psychopharmacology, 2009, 206, 653-664.	1.5	3
225	Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology, 2009, 206, 223-232.	1.5	21
226	Open vessel mode microwave-assisted synthesis of 2-oxazolines from carboxylic acids. Tetrahedron Letters, 2009, 50, 5780-5782.	0.7	17
227	Microwave-assisted synthesis of sodium sulfonates precursors of sulfonyl chlorides and fluorides. Tetrahedron Letters, 2009, 50, 7028-7031.	0.7	17
228	Latest advances in cannabinoid receptor agonists. Expert Opinion on Therapeutic Patents, 2009, 19, 1647-1673.	2.4	79
229	Dynamic Conformational Responses of a Human Cannabinoid Receptor-1 Helix Domain to Its Membrane Environment. Biochemistry, 2009, 48, 4895-4904.	1.2	13
230	Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 2009, 14, 43-65.	1.0	161
231	Solid-state NMR and molecular dynamics characterization of cannabinoid receptor-1 (CB1) helix 7 conformational plasticity in model membranes. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1159-1167.	1.4	19
232	Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. Biochemical and Biophysical Research Communications, 2009, 384, 243-248.	1.0	17
233	NMR solution structure of human cannabinoid receptor-1 helix 7/8 peptide: Candidate electrostatic interactions and microdomain formation. Biochemical and Biophysical Research Communications, 2009, 390, 441-446.	1.0	18
234	Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?. Trends in Pharmacological Sciences, 2009, 30, 1-7.	4.0	122

#	Article	IF	Citations
235	Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies. International Review of Psychiatry, 2009, 21, 122-133.	1.4	30
236	Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands. Tetrahedron Letters, 2008, 49, 5587-5589.	0.7	16
237	Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology, 2008, 196, 565-574.	1.5	93
238	Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology, 2008, 198, 467-478.	1.5	17
239	Azido- and Isothiocyanato-Substituted Aryl Pyrazoles Bind Covalently to the CB1 Cannabinoid Receptor and Impair Signal Transduction. Journal of Neurochemistry, 2008, 74, 2174-2181.	2.1	13
240	Development of novel tail-modified anandamide analogs. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5912-5915.	1.0	10
241	A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5424-5427.	1.0	10
242	Covalent Inhibitors of Human Monoacylglycerol Lipase: Ligand-Assisted Characterization of the Catalytic Site by Mass Spectrometry and Mutational Analysis. Chemistry and Biology, 2008, 15, 854-862.	6.2	74
243	Ligand-Binding Architecture of Human CB2 Cannabinoid Receptor: Evidence for Receptor Subtype-Specific Binding Motif and Modeling GPCR Activation. Chemistry and Biology, 2008, 15, 1207-1219.	6.2	88
244	Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacology Biochemistry and Behavior, 2008, 91, 84-90.	1.3	36
245	The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology, 2008, 54, 129-140.	2.0	132
246	Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome. Physiology and Behavior, 2008, 93, 671-686.	1.0	84
247	Bornyl- and Isobornyl-Î”⁸-tetrahydrocannabinols: A Novel Class of Cannabinergic Ligands. Journal of Medicinal Chemistry, 2008, 51, 6393-6399.	2.9	26
248	The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behavioural Brain Research, 2008, 193, 298-305.	1.2	37
249	Magnetically Aligned Bicelles To Study the Orientation of Lipophilic Ligands in Membrane Bilayers. Journal of Medicinal Chemistry, 2008, 51, 6793-6799.	2.9	5
250	Full Mass Spectrometric Characterization of Human Monoacylglycerol Lipase Generated by Large-Scale Expression and Single-Step Purification. Journal of Proteome Research, 2008, 7, 2158-2164.	1.8	34
251	Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells. Journal of Immunology, 2008, 181, 6406-6416.	0.4	88
252	Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1289-95.	1.4	60

#	Article	IF	Citations
253	Selective Activation of Cannabinoid CB₂ Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 584-591.	1.3	103
254	Mapping the Structural Requirements in the CB₁Cannabinoid Receptor Transmembrane Helix II for Signal Transduction. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 341-348.	1.3	29
255	A neutral CB₁ receptor antagonist reduces weight gain in rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R2185-R2193.	0.9	88
256	Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1Transmembrane Helix 7. Molecular Pharmacology, 2007, 71, 1512-1524.	1.0	79
257	The Endogenous Cannabinoid Anandamide Produces Î´-9-Tetrahydrocannabinol-Like Discriminative and Neurochemical Effects That Are Enhanced by Inhibition of Fatty Acid Amide Hydrolase but Not by Inhibition of Anandamide Transport. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 370-380.	1.3	103
258	Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1059-1066.	1.3	83
259	Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats. Behavioural Pharmacology, 2007, 18, 673-680.	0.8	8
260	Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions. Physiology and Behavior, 2007, 91, 383-388.	1.0	127
261	Cannabilactones: A Novel Class of CB2 Selective Agonists with Peripheral Analgesic Activity. Journal of Medicinal Chemistry, 2007, 50, 6493-6500.	2.9	86
262	C1â€˜-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2007, 50, 4048-4060.	2.9	44
263	Comprehensive Proteomic Mass Spectrometric Characterization of Human Cannabinoid CB2 Receptor. Journal of Proteome Research, 2007, 6, 2068-2079.	1.8	22
264	Quantitative Method for the Profiling of the Endocannabinoid Metabolome by LC-Atmospheric Pressure Chemical Ionization-MS. Analytical Chemistry, 2007, 79, 5582-5593.	3.2	79
265	Expression and Function of Cannabinoid Receptors CB1 and CB2 and Their Cognate Cannabinoid Ligands in Murine Embryonic Stem Cells. PLoS ONE, 2007, 2, e641.	1.1	68
266	A concise methodology for the synthesis of (â^')-Î”9-tetrahydrocannabinol and (â^')-Î”9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs. Tetrahedron, 2007, 63, 8112-8123.	1.0	20
267	Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5959-5963.	1.0	11
268	Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. British Journal of Pharmacology, 2007, 150, 153-163.	2.7	91
269	Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology, 2007, 152, 765-777.	2.7	127
270	Targeted modulators of the endogenous cannabinoid system: Future medications to treat addiction disorders and obesity. Current Psychiatry Reports, 2007, 9, 365-373.	2.1	17

#	Article	IF	Citations
271	Plasma and brain endocannabinoid level correlation studies after increasing DHA dietary intake. FASEB Journal, 2007, 21, A1067.	0.2	2
272	Discriminative stimulus effects of methamphetamine and in vivo microdialysis in rats. FASEB Journal, 2007, 21, A776.	0.2	1
273	3D-QSAR Studies of Arylpyrazole Antagonists of Cannabinoid Receptor Subtypes CB1 and CB2. A Combined NMR and CoMFA Approach. Journal of Medicinal Chemistry, 2006, 49, 625-636.	2.9	59
274	CB2 cannabinoid receptor mediation of antinociception. Pain, 2006, 122, 36-42.	2.0	153
275	Irt>t schedule controlled behavior in â€˜learned-helplessâ€™ rats: Effects from a cannabinoid agonist. Neuropharmacology, 2006, 51, 90-101.	2.0	1
276	Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse, 2006, 60, 93-101.	0.6	23
277	Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. Bioorganic and Medicinal Chemistry, 2006, 14, 6666-6678.	1.4	19
278	Targeting the endocannabinoid system in treating brain disorders. Expert Opinion on Investigational Drugs, 2006, 15, 351-365.	1.9	46
279	Endocannabinoid metabolomics: A novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS Journal, 2006, 8, E655-E660.	2.2	18
280	Antagonism of discriminative stimulus effects of Î”9-THC and (R)-methanandamide in rats. Psychopharmacology, 2006, 184, 36-45.	1.5	39
281	Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Î”9-THC or (R)-methanandamide (AM-356). Psychopharmacology, 2006, 188, 315-323.	1.5	22
282	Structural modifications of the cannabinoid side chain towards C3-aryl and 1â€²,1â€²-cycloalkyl-1â€²-cyano cannabinoids. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1616-1620.	1.0	21
283	AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European Journal of Pharmacology, 2006, 542, 100-105.	1.7	132
284	Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacology Biochemistry and Behavior, 2006, 83, 396-402.	1.3	38
285	Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: Open-field examination in rats. Pharmacology Biochemistry and Behavior, 2006, 85, 243-252.	1.3	36
286	Cannabinoid Receptors as Therapeutic Targets. Current Pharmaceutical Design, 2006, 12, 1751-1769.	0.9	55
287	The Cannabinergic System as a Target for Anti-inflammatory Therapies. Current Topics in Medicinal Chemistry, 2006, 6, 1401-1426.	1.0	23
288	The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats. Behavioural Pharmacology, 2005, 16, 477-486.	0.8	14

#	Article	IF	Citations
289	Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. Chemical Biology and Drug Design, 2005, 66, 138-150.	1.2	26
290	Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology Biochemistry and Behavior, 2005, 81, 78-88.	1.3	34
291	How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins and Other Lipid Mediators, 2005, 77, 210-218.	1.0	44
292	The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology, 2005, 180, 286-293.	1.5	78
293	Cannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or Metabolism Enhance the Reinforcing Efficacy of Heroin in Rats. Neuropsychopharmacology, 2005, 30, 2046-2057.	2.8	92
294	CB1 Cannabinoid Receptor Ligands. Mini-Reviews in Medicinal Chemistry, 2005, 5, 631-640.	1.1	72
295	The Endocannabinoid System as a Target for Alkamides fromEchinacea angustifoliaRoots. Planta Medica, 2005, 71, 701-705.	0.7	88
296	Dual Modulation of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Protects against Excitotoxicity. Journal of Neuroscience, 2005, 25, 7813-7820.	1.7	109
297	CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3093-3098.	3.3	481
298	Structural Requirements for Cannabinoid Receptor Probes. , 2005, , 209-246.		43
299	Potent Cannabinergic Indole Analogues as Radioiodinatable Brain Imaging Agents for the CB1 Cannabinoid Receptor. Journal of Medicinal Chemistry, 2005, 48, 6386-6392.	2.9	43
300	Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 2005, 310, 329-332.	6.0	1,357
301	Novel 17Î²-Substituted Conformationally Constrained Neurosteroids that Modulate GABAAReceptors. Journal of Medicinal Chemistry, 2005, 48, 5203-5214.	2.9	27
302	High Affinity Electrophilic and Photoactivatable Covalent Endocannabinoid Probes for the CB1 Receptor. Journal of Medicinal Chemistry, 2005, 48, 6423-6429.	2.9	38
303	The Conformation, Location, and Dynamic Properties of the Endocannabinoid Ligand Anandamide in a Membrane Bilayer. Journal of Biological Chemistry, 2005, 280, 29788-29795.	1.6	67
304	Adamantyl Cannabinoids:Â A Novel Class of Cannabinergic Ligands. Journal of Medicinal Chemistry, 2005, 48, 4576-4585.	2.9	67
305	(-)-7â€²-Isothiocyanato-11-hydroxy-1â€²,1â€²-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2005, 68, 1623-1635.	1.0	86
306	Targeted lipidomics: endocannabinoids and other endolipid modulators. Life Sciences, 2005, 77, 1517-1518.	2.0	1

#	Article	IF	Citations
307	Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. Life Sciences, 2005, 77, 1605-1611.	2.0	19
308	Natural cannabinoids: Templates for drug discovery. Life Sciences, 2005, 78, 454-466.	2.0	72
309	The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1668, 1-9.	1.4	46
310	Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. Nuclear Medicine and Biology, 2005, 32, 361-366.	0.3	21
311	Drug Discrimination in Methamphetamine-Trained Monkeys: Effects of Monoamine Transporter Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 720-727.	1.3	23
312	Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8756-8761.	3.3	210
313	Selective Activation of Cannabinoid CB2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 446-453.	1.3	120
314	Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. British Journal of Pharmacology, 2004, 142, 495-500.	2.7	87
315	The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model. AAPS Journal, 2004, 6, 23-35.	2.2	35
316	Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology, 2004, 175, 170-8.	1.5	30
317	Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology, 2004, 177, 35-45.	1.5	23
318	Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Life Sciences, 2004, 74, 1001-1011.	2.0	18
319	Activation of Cannabinoid CB2Receptors Suppresses C-Fiber Responses and Windup in Spinal Wide Dynamic Range Neurons in the Absence and Presence of Inflammation. Journal of Neurophysiology, 2004, 92, 3562-3574.	0.9	102
320	(???)-Adamantyl-??8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behavioural Pharmacology, 2004, 15, 517-521.	0.8	24
321	(R)-Methanandamide and Î”9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. European Journal of Pharmacology, 2003, 466, 121-127.	1.7	28
322	The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacology Biochemistry and Behavior, 2003, 75, 809-821.	1.3	32
323	Synthesis of15N-,13C-, and2H-labeled methanandamide analogs. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 115-129.	0.5	7
324	Bifunctional agents for reperfusion arrhythmias: Novel hybrid vitamin E/Class I antiarrhythmics. Bioorganic and Medicinal Chemistry, 2003, 11, 5209-5219.	1.4	24

#	Article	IF	Citations
325	Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry, 2003, 84, 1097-1109.	2.1	133
326	Conformational Study of Lipophilic Ligands in Phospholipid Model Membrane Systems by Solution NMR. Journal of Medicinal Chemistry, 2003, 46, 4838-4846.	2.9	22
327	Synthesis of Covalent Probes for the Radiolabeling of the Cannabinoid Receptor. Journal of Organic Chemistry, 2003, 68, 55-61.	1.7	25
328	Pharmacophoric Requirements for the Cannabinoid Side Chain. Probing the Cannabinoid Receptor Subsite at C1â€˜. Journal of Medicinal Chemistry, 2003, 46, 3221-3229.	2.9	50
329	Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 2003, 119, 747-757.	1.1	158
330	CB cannabinoid receptor agonists: pain relief without psychoactive effects?. Current Opinion in Pharmacology, 2003, 3, 62-67.	1.7	193
331	Antileishmanial Ring-Substituted Ether Phospholipids. Journal of Medicinal Chemistry, 2003, 46, 755-767.	2.9	42
332	Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10529-10533.	3.3	457
333	The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioural Pharmacology, 2003, 14, 583-588.	0.8	155
334	Autocrine and Paracrine Regulation of Lymphocyte CB2 Receptor Expression by TGF-Î². Biochemical and Biophysical Research Communications, 2002, 290, 91-96.	1.0	54
335	Regiospecifically deuterated (â˜)-Î”9-tetrahydrocannabivarins. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 2544-2548.	1.3	10
336	A CONVENIENT AND EFFECTIVE SYNTHESIS OF 3-(3,5-DIMETHOXYPHENYL)PROPANAL. Synthetic Communications, 2002, 32, 1751-1756.	1.1	7
337	Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. Journal of Proteomics, 2002, 54, 415-422.	2.4	16
338	Synthesis of15N and13C selectively labeled anandamide. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 775-784.	0.5	1
339	Synthesis of side chain specifically deuterated (?)-?9-tetrahydrocannabinols. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1065-1076.	0.5	12
340	Ligand based structural studies of the CB1 cannabinoid receptor. Chemical Biology and Drug Design, 2002, 60, 348-356.	1.2	31
341	Novel 1â€²,1â€²-chain substituted Î”8-tetrahydrocannabinols. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3583-3586.	1.0	51
342	Cannabinergic ligands. Chemistry and Physics of Lipids, 2002, 121, 3-19.	1.5	131

#	Article	IF	Citations
343	Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chemistry and Physics of Lipids, 2002, 121, 191-200.	1.5	96
344	In vivo imaging of the brain cannabinoid receptor. Chemistry and Physics of Lipids, 2002, 121, 65-72.	1.5	31
345	Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bulletin of Experimental Biology and Medicine, 2002, 133, 122-124.	0.3	25
346	Endocannabinoids: Discovery of a unique signaling system for regulating sperm function and fertilization.. Fertility and Sterility, 2001, 76, S202-S203.	0.5	0
347	Endocannabinoids control spasticity in a multiple sclerosis model. FASEB Journal, 2001, 15, 300-302.	0.2	371
348	CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 2001, 93, 239-245.	2.0	346
349	The Cannabinoid Agonist WIN55,212-2 Suppresses Opioid-induced Emesis in Ferrets. Anesthesiology, 2001, 94, 882-887.	1.3	104
350	A New Ring-Forming Methodology for the Synthesis of Conformationally Constrained Bioactive Molecules. Chemistry Letters, 2001, 30, 192-193.	0.7	16
351	(R)-Methanandamide and Î” 9 -THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology, 2001, 156, 369-380.	1.5	79
352	Stereochemical Selectivity of Methanandamides for the CB1 and CB2 Cannabinoid Receptors and Their Metabolic Stability. Bioorganic and Medicinal Chemistry, 2001, 9, 1673-1684.	1.4	48
353	Preparation of optically pure 4-(hydroxymethyl)-2-pentadecyl-1,3-dioxolanes and their corresponding phosphodiester ether lipid derivatives. Chemistry and Physics of Lipids, 2001, 113, 111-122.	1.5	3
354	Ether Phospholipid-AZT Conjugates Possessing Anti-HIV and Antitumor Cell Activity. Synthesis, Conformational Analysis, and Study of Their Thermal Effects on Membrane Bilayers. Journal of Medicinal Chemistry, 2001, 44, 1702-1709.	2.9	33
355	Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine, 2001, 7, 827-832.	15.2	363
356	Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal, 2000, 346, 835-840.	1.7	284
357	Î”9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behavioural Pharmacology, 2000, 11, 81-86.	0.8	27
358	Molecular probes for the cannabinoid receptors. Chemistry and Physics of Lipids, 2000, 108, 37-52.	1.5	86
359	Synthesis of Functionalized Cannabinoids. Journal of Organic Chemistry, 2000, 65, 6576-6582.	1.7	41
360	Natural and Synthetic Endocannabinoids and Their Structure-Activity Relationships. Current Pharmaceutical Design, 2000, 6, 1381-1397.	0.9	49

#	Article	IF	Citations
361	Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal, 2000, 346 Pt 3, 835-40.	1.7	96
362	Structural determinants for recognition and translocation by the anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5802-5807.	3.3	263
363	Novel conformationally restricted tetracyclic analogs of Î”8-tetrahydrocannabinol. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2119-2124.	1.0	39
364	Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. British Journal of Pharmacology, 1999, 126, 665-672.	2.7	353
365	Structureâ^'Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 769-776.	2.9	428
366	Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPÎ³S binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Neurochemistry International, 1999, 34, 473-482.	1.9	23
367	Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sciences, 1999, 65, 327-336.	2.0	51
368	Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sciences, 1999, 65, 607-616.	2.0	51
369	Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. Journal of Medicinal Chemistry, 1999, 42, 896-902.	2.9	110
370	High-Resolution NMR and Computer Modeling Studies of the Cannabimimetic Aminoalkylindole Prototype WIN-55212-2. Journal of Medicinal Chemistry, 1999, 42, 4021-4027.	2.9	17
371	Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand. AAPS PharmSci, 1999, 1, 39-45.	1.3	71
372	Large receptor reserve for cannabinoid actions in the central nervous system. Journal of Pharmacology and Experimental Therapeutics, 1999, 288, 478-83.	1.3	83
373	Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic Î³-aminobutyric acid (GABA) inputs. Biochemical Pharmacology, 1998, 56, 1331-1338.	2.0	51
374	Determination of Anandamide Amidase Activity Using Ultraviolet-Active Amine Derivatives and Reverse-Phase High-Performance Liquid Chromatography. Analytical Biochemistry, 1998, 261, 8-15.	1.1	26
375	Addition and elimination of HCl to tetrahydrocannabinol isomers. A method for the preparation of stereospecifically 2H-labeled cannabinoids. Journal of Labelled Compounds and Radiopharmaceuticals, 1998, 41, 121-130.	0.5	2
376	A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology, 1998, 137, 147-156.	1.5	41
377	Î” 9 -THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology, 1998, 140, 519-522.	1.5	51
378	Pharmacophoric Requirements for Cannabinoid Side Chains:Â Multiple Bond and C1â€˜-Substituted Î”8-Tetrahydrocannabinols. Journal of Medicinal Chemistry, 1998, 41, 1195-1200.	2.9	68

#	Article	IF	Citations
379	AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sciences, 1998, 62, PL109-PL113.	2.0	46
380	Classical/Nonclassical Hybrid Cannabinoids:Â Southern Aliphatic Chain-Functionalized C-6Î² Methyl, Ethyl, and Propyl Analogues. Journal of Medicinal Chemistry, 1998, 41, 3596-3608.	2.9	54
381	Conformational Studies on a Diastereoisomeric Pair of Tricyclic Nonclassical Cannabinoids by NMR Spectroscopy and Computer Molecular Modeling. Journal of Medicinal Chemistry, 1998, 41, 167-174.	2.9	18
382	Novel Analogues of Arachidonylethanolamide (Anandamide):â€‰ Affinities for the CB1 and CB2 Cannabinoid Receptors and Metabolic Stability. Journal of Medicinal Chemistry, 1998, 41, 5353-5361.	2.9	132
383	Effects of Cannabinoids on Preimplantation Mouse Embryo Development and Implantation are Mediated by Brain-Type Cannabinoid Receptors1. Biology of Reproduction, 1998, 58, 1490-1495.	1.2	105
384	Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo. Journal of Neurochemistry, 1998, 70, 417-423.	2.1	105
385	Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. Behavioural Pharmacology, 1998, 9, 169-74.	0.8	20
386	Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition. Science, 1997, 277, 1094-1097.	6.0	755
387	Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: Evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochemical Pharmacology, 1997, 53, 1919-1927.	2.0	84
388	Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor. Biochemical and Biophysical Research Communications, 1997, 231, 217-221.	1.0	130
389	Differential scanning calorimetry and small angle x-ray diffraction study of the interaction of (R)-PAF, (R)-ET-18-OMe and (R)-Lyso-PAF with model membranes. Life Sciences, 1997, 61, 909-923.	2.0	10
390	AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sciences, 1997, 61, PL115-PL118.	2.0	46
391	Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neuroscience Letters, 1997, 238, 84-86.	1.0	66
392	Syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) and analogs with 13C- and 2H-labeled choline head groups. Chemistry and Physics of Lipids, 1997, 86, 171-181.	1.5	7
393	Title is missing!. Biotechnology Letters, 1997, 11, 885-888.	0.5	5
394	Head Group Analogs of Arachidonylethanolamide, the Endogenous Cannabinoid Ligand. Journal of Medicinal Chemistry, 1996, 39, 4515-4519.	2.9	166
395	Unsaturated Side Chain Î²-11-Hydroxyhexahydrocannabinol Analogs. Journal of Medicinal Chemistry, 1996, 39, 3790-3796.	2.9	70
396	Synthesis and Antiretroviral Evaluation of New Alkoxy and Aryloxy Phosphate Derivatives of 3â€˜-Azido-3â€˜-deoxythymidine. Journal of Medicinal Chemistry, 1996, 39, 3418-3422.	2.9	20

#	Article	IF	Citations
397	Model Investigations for Vanadiumâ^'Protein Interactions. Synthetic, Structural, and Physical Studies of Vanadium(III) and Oxovanadium(IV/V) Complexes with Amidate Ligands. Inorganic Chemistry, 1996, 35, 357-367.	1.9	88
398	The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940. Journal of Biological Chemistry, 1996, 271, 10640-10647.	1.6	53
399	Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1, receptor ligand. Life Sciences, 1996, 58, 1249-1257.	2.0	57
400	123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. European Journal of Pharmacology, 1996, 307, 331-338.	1.7	222
401	Topography and thermotropic properties of cannabinoids in brain sphingomyelin bilayers. Life Sciences, 1996, 59, 1969-1979.	2.0	6
402	Alkyl and Alkoxyethyl Antineoplastic Phospholipids. Journal of Medicinal Chemistry, 1996, 39, 2609-2614.	2.9	21
403	C-Attached aminoalkylindoles: potent cannabinoid mimetics. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 17-22.	1.0	31
404	Crystal structure of the meta hydroxyl phenyl analog of Î±(+)-prodine. Journal of Chemical Crystallography, 1996, 26, 601-605.	0.5	0
405	Preparation of iodine-123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 875-881.	0.5	20
406	High-Performance Liquid Chromatographic Determination of Anandamide Amidase Activity in Rat Brain Microsomes. Analytical Biochemistry, 1996, 238, 40-45.	1.1	44
407	The conformational properties of the antineoplastic ether lipid 1-thiohexadecyl-2-O-methyl-S-glycero-3-phosphocholine. Chemistry and Physics of Lipids, 1996, 84, 21-34.	1.5	8
408	Interactions of angiotensin II with membranes using a combination of differential scanning calorimetry and 31P NMR spectroscopy. International Journal of Peptide Research and Therapeutics, 1996, 3, 175-180.	0.1	7
409	Synthesis and anti-HIV Evaluation of Alkyl and Alkoxyethyl Phosphodiester AZT Derivatives. Antiviral Chemistry and Chemotherapy, 1995, 6, 43-49.	0.3	11
410	Single crystal X-ray structures of the two 4-heptadecyl derivatives of (1R,5S)-3,6,8-trioxabicylo[3.2.1]octane. Chemistry and Physics of Lipids, 1995, 77, 99-112.	1.5	1
411	Studies of the conformational properties of the cannabimimetic aminoalkylindole pravadoline using NMR and molecular modeling. European Journal of Medicinal Chemistry, 1995, 30, 227-234.	2.6	20
412	Small angle X-ray diffraction and differential scanning calorimetric studies on O-methyl-(â^')-Î”8-tetrahydrocannabinol and its 5â€² iodinated derivative in membrane bilayers. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1237, 183-188.	1.4	19
413	Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Lipids and Lipid Metabolism, 1995, 1259, 173-179.	2.6	111
414	Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. European Journal of Pharmacology, 1995, 272, 73-78.	1.7	68

#	Article	IF	Citations
415	AM630, a competitive cannabinoid receptor antagonist. Life Sciences, 1995, 56, 1949-1955.	2.0	130
416	A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sciences, 1995, 56, 1957-1962.	2.0	34
417	Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sciences, 1995, 56, 1963-1970.	2.0	26
418	Classical/non-classical cannabinoid hybrids; Stereochemical requirements for the southern hydroxyalkyl chain. Life Sciences, 1995, 56, 2007-2012.	2.0	18
419	Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity. Tetrahedron, 1994, 50, 2671-2680.	1.0	27
420	Chiral resolution of 1,3-dimethyl-4-phenylpiperidine derivatives using high-performance liquid chromatography with a chiral stationary phase. Journal of Chromatography A, 1994, 678, 176-179.	1.8	9
421	Synthesis and Pharmacological Properties of 11-Hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: A High Affinity Cannabinoid Agonist. Journal of Medicinal Chemistry, 1994, 37, 2619-2622.	2.9	26
422	(R)-Methanandamide: A Chiral Novel Anandamide Possessing Higher Potency and Metabolic Stability. Journal of Medicinal Chemistry, 1994, 37, 1889-1893.	2.9	324
423	Structure and Orientation of the Pore-forming Peptide Melittin, in Lipid Bilayers. Journal of Molecular Biology, 1994, 241, 456-466.	2.0	165
424	(-)-11-Hydroxy-7'-isothiocyanato-1',1'- dimethylheptyl-.DELTA.8-THC: A Novel, High-Affinity Irreversible Probe for the Cannabinoid Receptor in the Brain. Journal of Medicinal Chemistry, 1994, 37, 3867-3870.	2.9	39
425	Syntheses of Racemic and Nearly Optically Pure Ether Lipids and Evaluation of in vitro Antineoplastic Activities. Journal of Medicinal Chemistry, 1994, 37, 4147-4154.	2.9	11
426	Conformational Analysis of the Prototype Nonclassical Cannabinoid CP-47,497, Using 2D NMR and Computer Molecular Modeling. Journal of Medicinal Chemistry, 1994, 37, 1418-1426.	2.9	32
427	Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II. Journal of Biological Chemistry, 1994, 269, 5303-12.	1.6	54
428	Pharmacological evaluation of iodo and nitro analogs of Î”8-THC and Î”9-THC. Pharmacology Biochemistry and Behavior, 1993, 46, 295-301.	1.3	36
429	Conformational analysis of the opioid phenylmorphan and its 9 alpha-methyl analogue in solution using high-resolution nuclear magnetic resonance spectroscopy. Pharmaceutical Research, 1993, 10, 1200-1205.	1.7	2
430	Small angle X-ray diffraction studies of (â˜)-Î”8-tetrahydrocannabinol and its O-methyl analog in membranes. Life Sciences, 1993, 53, PL117-PL122.	2.0	13
431	Probes for the cannabinoid sites of action. NIDA Research Monograph, 1993, 134, 253-67.	0.1	3
432	Hallucinogenic receptor models: interaction of imidazolium chloride with amphetamine analogs. Molecular Pharmacology, 1993, 43, 78-83.	1.0	0

#	Article	IF	Citations
433	Syntheses of all four stereoisomers which are conformationally constrained 1,4-dioxanyl analogs of the antineoplastic ether lipid ET-18-OCH3. Journal of Organic Chemistry, 1992, 57, 6156-6163.	1.7	19
434	Conformational preferences of the .kappa.-selective opioid agonist U50488. A combined molecular mechanics and nuclear magnetic resonance study. Journal of Medicinal Chemistry, 1992, 35, 3085-3094.	2.9	14
435	5'-Azido-.DELTA.8-THC: a novel photoaffinity label for the cannabinoid receptor. Journal of Medicinal Chemistry, 1992, 35, 3076-3079.	2.9	40
436	Amphipathic interactions of cannabinoids with membranes. A comparison between Î”8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1103, 25-36.	1.4	41
437	Anesthetic steroid mobility in model membrane preparations examined by high-resolution proton and deuterium NMR spectroscopy. Journal of Medicinal Chemistry, 1991, 34, 1700-1703.	2.9	22
438	Detection of cannabinoid receptors by photoaffinity labelling. Biochemical and Biophysical Research Communications, 1991, 176, 492-497.	1.0	22
439	PET studies in the primate brain and biodistribution in mice using (â^')-5â€²-18F-Î”8-THC. Pharmacology Biochemistry and Behavior, 1991, 40, 503-507.	1.3	47
440	Pharmacological evaluation of halogenated Î”8-THC analogs. Pharmacology Biochemistry and Behavior, 1991, 40, 509-512.	1.3	31
441	Small angle X-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes. Pharmacology Biochemistry and Behavior, 1991, 40, 547-552.	1.3	21
442	Solid state 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes. Pharmacology Biochemistry and Behavior, 1991, 40, 553-557.	1.3	17
443	Combined use of solid-state nuclear magnetic resonance spectroscopy, small-angle x-ray diffraction, and differential scanning calorimetry in studies of cannabinoid: membrane interactions. NIDA Research Monograph, 1991, 112, 106-28.	0.1	1
444	Chirospecific syntheses of 2H- and 13C-labeled 1-O-alkyl-2-O-alkylâ€²-sn-glycero-3-phosphoethanolamines and 1-O-alkyl-2-O-alkylâ€²-sn-glycero-3-phosphocholines. Chemistry and Physics of Lipids, 1990, 54, 49-59.	1.5	8
445	The perturbation of model membranes by (â^')-Î”9-tetrahydrocannabinol. Studies using solid-state 2H- and 13C-NMR. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1028, 31-42.	1.4	28
446	Study of the topography of cannabinoids in model membranes using X-ray diffraction. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1024, 336-344.	1.4	41
447	The molecular basis of cannabinoid activity. Life Sciences, 1990, 47, 2173-2184.	2.0	86
448	The Molecular Features of Membrane Perturbation by Anaesthetic Steroids: A Study Using Differential Scanning Calorimetry, Small Angle Xâ€Ray Diffraction and Solid State ² H NMR. Novartis Foundation Symposium, 1990, 153, 172-189.	1.2	7
449	Syntheses of 2H- and 13C-labeled 1,2-di-O-hexadecyl-sn-glycero-3-phosphoethanolamines and 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholines. Chemistry and Physics of Lipids, 1989, 50, 163-169.	1.5	9
450	Characterization of the L.lambda. phase in trehalose-stabilized dry membranes by solid-state NMR and x-ray diffraction. Biochemistry, 1989, 28, 5000-5009.	1.2	86

#	Article	IF	Citations
451	The orientation of (â^')-Î”9-tetrahydrocannabinol in DPPC bilayers as determined from solid-state 2H-NMR. Biochimica Et Biophysica Acta - Biomembranes, 1989, 986, 141-145.	1.4	34
452	The conformational analysis of delta 9- and delta 9,11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. Molecular Pharmacology, 1989, 35, 495-503.	1.0	18
453	Synthesis of deuterium labeled cannabinoids. Journal of Labelled Compounds and Radiopharmaceuticals, 1988, 25, 73-82.	0.5	16
454	Novel synthesis of (â^')-trans-Î”9,11-tetrahydrocannabinol. Journal of Heterocyclic Chemistry, 1988, 25, 823-825.	1.4	3
455	The conformation of (-) 8 Î± and (-) 8 Î²-hydroxy-Î´9-tetrahydrocannabinols and their interactions with model membranes. Life Sciences, 1988, 42, 2231-2239.	2.0	8
456	Separation of Tetrahydrocannabinol Isomers by Reverse-Phase High Pressure Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 2931-2938.	0.9	5
457	Specific deuteration of phenols and aromatic ethers using boron trifluoride and deuterium oxide. Journal of Labelled Compounds and Radiopharmaceuticals, 1987, 24, 1479-1482.	0.5	7
458	Interactions of cannabinoids with membranes. The role of cannabinoid stereochemistry and absolute configuration and the orientation of delta-9-THC in the membrane bilayer. NIDA Research Monograph, 1987, 79, 123-33.	0.1	5
459	The medicinal chemistry of cannabinoids: an overview. NIDA Research Monograph, 1987, 79, 204-10.	0.1	7
460	Geometric requirements for membrane perturbation and anesthetic activity. Conformational analysis of alphaxalone and delta 16-alphaxalone and 2H NMR studies on their interactions with model membranes. Molecular Pharmacology, 1985, 27, 624-9.	1.0	28
461	Mechanism of steroid anesthetic action: interactions of alphaxalone and .DELTA.16-alphaxalone with bilayer vesicles. Journal of Medicinal Chemistry, 1983, 26, 463-465.	2.9	21
462	Conformational requirements for norepinephrine uptake inhibition by phenethylamines in brain synaptosomes. Effects of .alpha.-alkyl substitution. Journal of Medicinal Chemistry, 1982, 25, 1438-1441.	2.9	6
463	Methoxy group conformations of phenyl methyl ethers in solution. Journal of the American Chemical Society, 1982, 104, 6462-6463.	6.6	65
464	Studies on phenethylamine hallucinogens. 2. Conformations of arylmethoxyl groups by carbon-13 NMR. Journal of Medicinal Chemistry, 1981, 24, 906-909.	2.9	21
465	Synthesis and adrenoceptor affinity of some highly polar .beta.-substituted catecholamines. Journal of Medicinal Chemistry, 1981, 24, 1258-1260.	2.9	6
466	Conformational analysis of amphetamine in solution based on unambiguous assignment of the diastereotopic benzylic protons in the 1H NMR spectra. Tetrahedron Letters, 1981, 22, 4631-4634.	0.7	11
467	Effects of anesthetics on sulfate transport in the red cell. Journal of Neuroscience Research, 1980, 5, 25-33.	1.3	10
468	Conformational energy differences between side chain alkylated analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. Journal of Medicinal Chemistry, 1980, 23, 339-341.	2.9	6

#	Article	IF	Citations
469	Nortropacocaine Hydrochloride Conformation in Aqueous and Hydrophobic Media. Journal of Pharmaceutical Sciences, 1979, 68, 788-790.	1.6	2
470	The conformational analysis of aromatic methoxyl groups from carbon-13 chemical shifts and spin-lattice relaxation times. Tetrahedron Letters, 1979, 20, 2753-2756.	0.7	23
471	Carbonâ€13 and proton magnetic resonance spectra of 2,4â€disubstituted 3,3â€diphenyltetrahydrofurans derived from isomethadone and isomethadol. Journal of Heterocyclic Chemistry, 1979, 16, 1223-1226.	1.4	1
472	A direct approach to the determination of the rotational barriers of the acetylcholine and choline molecules. Biochemical Pharmacology, 1979, 28, 1911-1915.	2.0	7
473	Mechanisms of local anesthetic action on the permeability of erythrocytes, leukocytes, and liposomes containing the erythrocyte anion channel protein. Molecular Pharmacology, 1977, 13, 840-51.	1.0	16
474	Selenol esters as specific reagents of the acylation of thiol groups. Journal of the American Chemical Society, 1973, 95, 8403-8406.	6.6	23
475	Azodicarboxylic acid esters as dealkylating agents. Journal of Organic Chemistry, 1973, 38, 1652-1657.	1.7	47
476	3-Phenyl-5-quinolinemethanol antimalarials. Journal of Medicinal Chemistry, 1973, 16, 118-122.	2.9	8
477	Conformational Relationships Between Analogs of Acetylcholine and Those of Local Anesthetics in Solution. Proceedings of the National Academy of Sciences of the United States of America, 1972, 69, 3416-3419.	3.3	16